FindTrial
Sign In

Efficacy of function defection: dipeptidyl peptidase-IV inhibitor combined with motor imagery under hyperbaric oxygen in the treatment of silent cerebral infarction in diabetic nephropathy

Efficacy of function defection: dipeptidyl peptidase-IV inhibitor combined with motor imagery under hyperbaric oxygen in the treatment of silent cerebral infarction in diabetic nephropathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012590
Enrollment
Unknown
Registered
2017-09-05
Start date
2017-09-08
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy complicated with silent cerebral infarction

Interventions

diabetic nephropathy patients with silent cerebral infarction group 1:DPP-IV treatment
diabetic nephropathy patients with silent cerebral infarction group 2:DPP-IV combined with motor imagery under hyperbaric oxygen
diabetic nephropathy patients without silent cerebral infarction group 1:DPP-IV treatment
diabetic nephropathy patients without silent cerebral infarction group 2:DPP-IV combined with motor imagery under hyperbaric oxygen

Sponsors

the Chongqing General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 76 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria patient of diabetic nephropathy with silent cerebral infarction

Exclusion criteria

Exclusion criteria: Patient or his/her family member do not agree to participate in this study

Design outcomes

Primary

MeasureTime frame
treatment effect;—

Countries

China

Contacts

Public ContactChen Danyan

Chongqing General Hospital

clioyoyo@163.com+86 15310626597

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026